Reduced transforming growth factor-β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura-Reference-Cited by-同舟云学术

Reduced transforming growth factor-β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura

Published:2002-03 Issue:4 Volume:116 Page:862-867
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Andersson Per-Ola,Olsson Anna,Wadenvik Hans

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.0007-1048.2002.03345.x/fullpdf

Reference37 articles.

1. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura;Andersson;Annals of Hematology,2000

2. Management of chronic immune thrombocytopenic purpura in children and adults;Blanchette;Seminars in Hematology,1998

3. Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4 (+) T cell lines;Bridoux;Journal of Experimental Medicine,1997

4. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis;Chen;Science,1994

5. Transforming growth factor beta 1 has differential effects on B cell proliferation and activation antigen expression;Cross;Journal of Immunology,1990

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials;Thrombosis Research;2024-02

2. Interleukin-37, vascular endothelial growth factor A, and transforming growth factor-β1: promising biomarkers in primary immune thrombocytopenia;Expert Review of Hematology;2022-07-13

3. Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms;Medicina;2022-02-01

4. Recent advances in the mechanisms and treatment of immune thrombocytopenia;eBioMedicine;2022-02

5. Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia;Blood;2021-04-19